Table 1 Clinical characteristics and baseline data of the participants
Variables | Placebo group (n = 24) | 200 mg group (n = 30) | 400 mg group (n = 24) | P1 | P2 | P3 |
|---|---|---|---|---|---|---|
General information | ||||||
Gender (%) | ||||||
Male | 21 (87.5) | 19 (61.3) | 16 (66.7) | 0.0304 | 0.0860 | 0.6810 |
Female | 3 (12.5) | 12 (38.7) | 8 (33.3) | |||
Age (years) | 30.4 ± 7.61 | 35.9 ± 12.50 | 33.5 ± 10.50 | 0.0653 | 0.2502 | 0.4585 |
Body weight (kg) | 67.75 ± 11.79 | 67.22 ± 12.97 | 62.03 ± 10.34 | 0.8780 | 0.0807 | 0.1145 |
BMI (kg/m2) | 23.39 ± 3.09 | 23.76 ± 3.81 | 22.18 ± 2.68 | 0.6999 | 0.1535 | 0.0895 |
Viral load (log10 copies/mL) | 7.13 ± 1.02 | 6.62 ± 1.52 | 7.41 ± 0.85 | 0.1665 | 0.2964 | 0.0259 |
COVID-19 severity (%) | ||||||
Mild | 23 (95.8) | 31 (100.0) | 22 (91.7) | 0.2514 | 0.5510 | 0.1016 |
Moderate | 1 (4.2) | 0 | 2 (8.3) | |||
Severe | 0 | 0 | 0 | |||
History of vaccination (%) | ||||||
Yes | 23 (95.8) | 29 (93.5) | 22 (91.7) | 0.7113 | 0.5510 | 0.7898 |
No | 1 (4.2) | 2 (6.5) | 2 (8.3) | |||
Time from administration to onset (days) | 4.8 ± 0.79 | 4.5 ± 0.81 | 5.0 ± 1.38 | 0.2894 | 0.4464 | 0.1106 |
High risk factors of COVID-19 (%) | 0.3745 | NA | 0.3745 | |||
Yes | 0 | 1 (3.2) | 0 | |||
No | 24 (100.0) | 30 (96.8) | 24 (100.0) | |||
History of allergy (%) | ||||||
Yes | 2 (8.3) | 0 | 0 | 0.1016 | 0.1486 | NA |
No | 22 (91.7) | 31 (100.0) | 24 (100.0) | |||
Vaccination within 1 month (%) | ||||||
Yes | 0 | 0 | 0 | NA | NA | NA |
No | 24 (100.0) | 31 (100.0) | 24 (100.0) | |||
Time since the last COVID-19 vaccination (days) | 23 | 29 | 22 | 0.1007 | 0.3704 | 0.4946 |
Attention of the other COVID-19 related clinical trials (%) | 0.2514 | > 0.9999 | 0.2514 | |||
Yes | 1 (4.2) | 0 | 1 (4.2) | |||
No | 23 (95.8) | 31 (100.0) | 23 (95.8) |